Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Achari Ventures I Extends Deadline, Secures up to $350K From Merger Partner Vaso | 1 | The SPAC Conference | ||
10.04. | Achari Ventures I Files Proxy on $176M Vaso Deal | 1 | The SPAC Conference | ||
01.04. | Vasomedical reports Q4 results | 1 | Seeking Alpha | ||
01.04. | Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2023 | 48 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO) today announced its operating results for the three months and year ended December 31, 2023. "The Company... ► Artikel lesen | |
01.04. | VASO Corp - 10-K, Annual Report | 1 | SEC Filings | ||
21.02. | Should You Hold Vaso Corporation (VASO)? | 1 | Insider Monkey | ||
08.12.23 | MedTech Co. Vaso Combining with Achari Ventures Holdings I in $176M Deal | 2 | The SPAC Conference | ||
08.12.23 | Vaso Corporation set to merge with Achari Ventures, uplist to Nasdaq | 1 | Investing.com | ||
08.12.23 | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
07.12.23 | Vaso to list on Nasdaq via SPAC merger | 1 | Seeking Alpha | ||
07.12.23 | Vaso Corporation, a Diversified Medical Technology Company Currently Trading on the OTCQX Market, to List on Nasdaq via SPAC Merger | 499 | ACCESSWIRE | Business Combination with Achari Ventures Holdings Corp. I is Expected to Be Completed in First Quarter of 2024Merger with Achari Ventures Holdings Corp. I (NASDAQ:AVHI) expected to improve capital... ► Artikel lesen | |
14.11.23 | Vasomedical reports Q3 results | 1 | Seeking Alpha | ||
14.11.23 | Vaso Corporation Announces Financial Results for Third Quarter 2023 | 310 | ACCESSWIRE | Making it the sixth consecutive quarter of profitabilityPLAINVIEW, NY / ACCESSWIRE / November 14, 2023 / Vaso Corporation ("Vaso") (OTCQX:VASO) today reported its operating results for the three months... ► Artikel lesen | |
25.09.23 | Vaso Corporation Announces Upgrade to OTCQX Best Market from OTCQB Venture Market | 383 | ACCESSWIRE | PLAINVIEW, NY / ACCESSWIRE / September 25, 2023 / Vaso Corporation ("Vaso") (OTCQB:VASO) today announced that its application to trade on the OTCQX Best Market has been approved by OTC Markets Group... ► Artikel lesen | |
14.08.23 | Vaso Corporation Announces Financial Results for Second Quarter 2023 | 343 | ACCESSWIRE | Company reports continued growth in revenue and record profitabilityPLAINVIEW, NY / ACCESSWIRE / August 14, 2023 / Vaso Corporation ("Vaso") (OTCQB:VASO) today reported its operating results for the... ► Artikel lesen | |
15.05.23 | Vaso Corporation Announces Financial Results for First Quarter 2023 | 311 | ACCESSWIRE | Revenue and Profitability Continued to Improve Year-over-yearPLAINVIEW, NY / ACCESSWIRE / May 15, 2023 / Vaso Corporation ("Vaso") (OTCQB:VASO) today reported its operating results for the three months... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 26,895 | -0,28 % | Bayer: Aktie verliert weiter - Unterstützung in Gefahr | Die Erholung bei der Bayer-Aktie Ende März war schnell wieder beendet. Zuletzt stand die Aktie erneut unter Druck. Auch am heutigen Freitagmorgen geht es weiter nach unten. Auf der Handelsplattform... ► Artikel lesen | |
ASTRAZENECA | 141,15 | +6,45 % | JPMORGAN stuft ASTRAZENECA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Astrazeneca vor den am 25. April erwarteten Quartalszahlen auf "Overweight" mit einem Kursziel von 13000 Pence belassen. Er liege mit Blick auf... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 15,310 | +1,59 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients... ► Artikel lesen | |
SANOCHEMIA PHARMAZEUTIKA | - | - | Nachlese: Magnus Brunner vs. FMA" EOSS holt nach Sanochemia auch BDI BioEnergy; Bettina Pfluger (Christian Drastil) | Um 12:12 liegt der ATX mit +0.03 Prozent im Plus bei 3452 Punkten (Ultimo 2023: 3435, 0.49% ytd). Topperformer der PIR-Group sind Addiko Bank mit +1.82% auf 15.425 Euro, dahinter DO&CO mit +1.79% auf... ► Artikel lesen | |
IONIS PHARMACEUTICALS | 39,260 | +0,67 % | Ionis Pharmaceuticals, Inc.: Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome | - Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events -
-... ► Artikel lesen | |
CSPC PHARMA | 0,752 | +3,73 % | CSPC Pharmaceutical Group-Aktie kann Vortagsniveau nicht halten (0,686 €) | Im Minus liegt zur Stunde die Aktie der CSPC Pharmaceutical Group . Das Wertpapier kostete zuletzt 0,69 Euro. An der Börse liegt die CSPC Pharmaceutical Group-Aktie aktuell im Minus. Die Aktie verbilligte... ► Artikel lesen | |
ACADIA PHARMACEUTICALS | 15,540 | +2,17 % | Aktien New York: Indizes bauen Gewinne aus - Inflationsdaten im Fokus | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben nach einem trägen Wochenstart am Dienstag zugelegt. Allerdings reagierten die Aktienkurse erst mit einiger Verzögerung positiv auf US-Inflationsdaten... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 1,418 | 0,00 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update | Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified Biomarkers... ► Artikel lesen | |
MADRIGAL PHARMACEUTICALS | 181,35 | +0,03 % | Madrigal Pharmaceuticals, Inc.: Madrigal Statement on the Passing of Dr. Stephen Harrison | ||
CATALYST PHARMACEUTICALS | 13,855 | +1,21 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 | ||
OCUPHIRE PHARMA | 1,448 | +1,12 % | Ocuphire Pharma: First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery | LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP)... ► Artikel lesen | |
ENZON PHARMACEUTICALS | 0,056 | -3,45 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 17.11.2023 | The following instruments on Boerse Frankfurt do have their last trading day on 17.11.2023Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 17.11.2023ISIN NameAU000000DCN6 DACIAN... ► Artikel lesen | |
DMK PHARMACEUTICALS | 0,049 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 2 | The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameLU0102219945 G.SACHS... ► Artikel lesen | |
CHUGAI PHARMACEUTICAL | 29,280 | -0,48 % | Chugai Pharmaceutical reports Q1 results | ||
ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information | Conference Call Scheduled for Thursday, February 15 at 11:30 AM ESTNORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pharmaceutical... ► Artikel lesen |